Logo image of GRFS

GRIFOLS SA-ADR (GRFS) Stock Fundamental Analysis

NASDAQ:GRFS - Nasdaq - US3984384087 - ADR - Currency: USD

7.22  -0.23 (-3.09%)

After market: 7.22 0 (0%)

Fundamental Rating

5

Overall GRFS gets a fundamental rating of 5 out of 10. We evaluated GRFS against 563 industry peers in the Biotechnology industry. There are concerns on the financial health of GRFS while its profitability can be described as average. GRFS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

GRFS had positive earnings in the past year.
GRFS had a negative operating cash flow in the past year.
In the past 5 years GRFS has always been profitable.
In multiple years GRFS reported negative operating cash flow during the last 5 years.
GRFS Yearly Net Income VS EBIT VS OCF VS FCFGRFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

1.2 Ratios

GRFS has a Return On Assets of 0.73%. This is amongst the best in the industry. GRFS outperforms 90.94% of its industry peers.
With an excellent Return On Equity value of 2.67%, GRFS belongs to the best of the industry, outperforming 92.72% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 3.86%, GRFS belongs to the top of the industry, outperforming 93.07% of the companies in the same industry.
GRFS had an Average Return On Invested Capital over the past 3 years of 2.90%. This is significantly below the industry average of 14.24%.
The 3 year average ROIC (2.90%) for GRFS is below the current ROIC(3.86%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.73%
ROE 2.67%
ROIC 3.86%
ROA(3y)0.66%
ROA(5y)1.4%
ROE(3y)2.39%
ROE(5y)4.54%
ROIC(3y)2.9%
ROIC(5y)3.1%
GRFS Yearly ROA, ROE, ROICGRFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

GRFS has a better Profit Margin (2.18%) than 91.83% of its industry peers.
In the last couple of years the Profit Margin of GRFS has declined.
GRFS has a Operating Margin of 16.02%. This is amongst the best in the industry. GRFS outperforms 95.74% of its industry peers.
GRFS's Operating Margin has declined in the last couple of years.
GRFS's Gross Margin of 38.75% is fine compared to the rest of the industry. GRFS outperforms 74.42% of its industry peers.
In the last couple of years the Gross Margin of GRFS has declined.
Industry RankSector Rank
OM 16.02%
PM (TTM) 2.18%
GM 38.75%
OM growth 3Y11.99%
OM growth 5Y-6.16%
PM growth 3Y-17.15%
PM growth 5Y-29.24%
GM growth 3Y-0.88%
GM growth 5Y-3.34%
GRFS Yearly Profit, Operating, Gross MarginsGRFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GRFS is destroying value.
The number of shares outstanding for GRFS remains at a similar level compared to 1 year ago.
The number of shares outstanding for GRFS remains at a similar level compared to 5 years ago.
The debt/assets ratio for GRFS has been reduced compared to a year ago.
GRFS Yearly Shares OutstandingGRFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GRFS Yearly Total Debt VS Total AssetsGRFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

GRFS has an Altman-Z score of 1.16. This is a bad value and indicates that GRFS is not financially healthy and even has some risk of bankruptcy.
GRFS's Altman-Z score of 1.16 is fine compared to the rest of the industry. GRFS outperforms 68.21% of its industry peers.
A Debt/Equity ratio of 1.48 is on the high side and indicates that GRFS has dependencies on debt financing.
GRFS has a Debt to Equity ratio of 1.48. This is amonst the worse of the industry: GRFS underperforms 80.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Altman-Z 1.16
ROIC/WACC0.68
WACC5.71%
GRFS Yearly LT Debt VS Equity VS FCFGRFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

GRFS has a Current Ratio of 2.66. This indicates that GRFS is financially healthy and has no problem in meeting its short term obligations.
GRFS's Current ratio of 2.66 is on the low side compared to the rest of the industry. GRFS is outperformed by 69.09% of its industry peers.
A Quick Ratio of 1.01 indicates that GRFS should not have too much problems paying its short term obligations.
The Quick ratio of GRFS (1.01) is worse than 87.74% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 1.01
GRFS Yearly Current Assets VS Current LiabilitesGRFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 285.83% over the past year.
Measured over the past years, GRFS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -23.99% on average per year.
Looking at the last year, GRFS shows a quite strong growth in Revenue. The Revenue has grown by 9.41% in the last year.
Measured over the past years, GRFS shows a small growth in Revenue. The Revenue has been growing by 7.18% on average per year.
EPS 1Y (TTM)285.83%
EPS 3Y-6.22%
EPS 5Y-23.99%
EPS Q2Q%26.88%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.5%
Revenue growth 5Y7.18%
Sales Q2Q%11.66%

3.2 Future

Based on estimates for the next years, GRFS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.59% on average per year.
The Revenue is expected to grow by 5.43% on average over the next years.
EPS Next Y42.14%
EPS Next 2Y37.01%
EPS Next 3Y30.46%
EPS Next 5Y17.59%
Revenue Next Year7.32%
Revenue Next 2Y7.32%
Revenue Next 3Y6.93%
Revenue Next 5Y5.43%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GRFS Yearly Revenue VS EstimatesGRFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
GRFS Yearly EPS VS EstimatesGRFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 27.77, which means the current valuation is very expensive for GRFS.
Based on the Price/Earnings ratio, GRFS is valued cheaper than 94.85% of the companies in the same industry.
GRFS's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 28.10.
Based on the Price/Forward Earnings ratio of 8.14, the valuation of GRFS can be described as reasonable.
97.69% of the companies in the same industry are more expensive than GRFS, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of GRFS to the average of the S&P500 Index (20.74), we can say GRFS is valued rather cheaply.
Industry RankSector Rank
PE 27.77
Fwd PE 8.14
GRFS Price Earnings VS Forward Price EarningsGRFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GRFS indicates a rather cheap valuation: GRFS is cheaper than 97.51% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 9.7
GRFS Per share dataGRFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

GRFS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of GRFS may justify a higher PE ratio.
A more expensive valuation may be justified as GRFS's earnings are expected to grow with 30.46% in the coming years.
PEG (NY)0.66
PEG (5Y)N/A
EPS Next 2Y37.01%
EPS Next 3Y30.46%

More info and screens

0

5. Dividend

5.1 Amount

GRFS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRIFOLS SA-ADR

NASDAQ:GRFS (5/6/2025, 4:30:01 PM)

After market: 7.22 0 (0%)

7.22

-0.23 (-3.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-12 2025-05-12
Inst Owners33.7%
Inst Owner Change0.61%
Ins Owners6.01%
Ins Owner ChangeN/A
Market Cap4.91B
Analysts73.68
Price Target14.3 (98.06%)
Short Float %0.8%
Short Ratio1.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-66.87%
DP0.61%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.33%
PT rev (3m)0.84%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-5.68%
EPS NY rev (3m)-13.83%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.05%
Revenue NY rev (3m)-0.82%
Valuation
Industry RankSector Rank
PE 27.77
Fwd PE 8.14
P/S 0.6
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB N/A
EV/EBITDA 9.7
EPS(TTM)0.26
EY3.6%
EPS(NY)0.89
Fwd EY12.29%
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS12.04
BVpS9.82
TBVpS-7.42
PEG (NY)0.66
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 2.67%
ROCE 6%
ROIC 3.86%
ROICexc 4.12%
ROICexgc 9.65%
OM 16.02%
PM (TTM) 2.18%
GM 38.75%
FCFM N/A
ROA(3y)0.66%
ROA(5y)1.4%
ROE(3y)2.39%
ROE(5y)4.54%
ROIC(3y)2.9%
ROIC(5y)3.1%
ROICexc(3y)3.07%
ROICexc(5y)3.33%
ROICexgc(3y)6.89%
ROICexgc(5y)7.47%
ROCE(3y)4.51%
ROCE(5y)4.82%
ROICexcg growth 3Y11.6%
ROICexcg growth 5Y-8.62%
ROICexc growth 3Y14.21%
ROICexc growth 5Y-7.74%
OM growth 3Y11.99%
OM growth 5Y-6.16%
PM growth 3Y-17.15%
PM growth 5Y-29.24%
GM growth 3Y-0.88%
GM growth 5Y-3.34%
F-Score6
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 1.48
Debt/FCF N/A
Debt/EBITDA 6.88
Cap/Depr 56.86%
Cap/Sales 0.83%
Interest Coverage 3.4
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 1.01
Altman-Z 1.16
F-Score6
WACC5.71%
ROIC/WACC0.68
Cap/Depr(3y)62.1%
Cap/Depr(5y)77.33%
Cap/Sales(3y)1.39%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)285.83%
EPS 3Y-6.22%
EPS 5Y-23.99%
EPS Q2Q%26.88%
EPS Next Y42.14%
EPS Next 2Y37.01%
EPS Next 3Y30.46%
EPS Next 5Y17.59%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.5%
Revenue growth 5Y7.18%
Sales Q2Q%11.66%
Revenue Next Year7.32%
Revenue Next 2Y7.32%
Revenue Next 3Y6.93%
Revenue Next 5Y5.43%
EBIT growth 1Y60.87%
EBIT growth 3Y27.11%
EBIT growth 5Y0.58%
EBIT Next Year55.01%
EBIT Next 3Y23.94%
EBIT Next 5Y18.42%
FCF growth 1Y-79.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.33%
OCF growth 3YN/A
OCF growth 5YN/A